F3M.F Tempus AI
- Market cap
- EUR 13.4B
- P/E
- -
- P/B
- 30.49x
- ROE
- -36.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is F3M.F undervalued?
Graham numberThe Graham number of Tempus AI cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tempus AI fundamental analysis
No fundamental analysis for Tempus AI yet.
Tempus AI stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tempus AI
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS te…
Full company profileTempus AI financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tempus AI annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 258M | 321M | 532M | 693M | 1.27B | 1.52B |
| Gross Profit | 83.6M | 130M | 286M | 381M | 798M | 980M |
| Operating Income | -244M | -265M | -196M | -691M | -253M | -290M |
| EBITDA | - | -237M | -133M | -610M | -119M | -22.4M |
| Net Income | -259M | -290M | -214M | -706M | -245M | -180M |
| EPS | -1.57 | -1.76 | -1.30 | -4.36 | -1.37 | -0.99 |
| Balance Sheet | ||||||
| Total Assets | 531M | 631M | 564M | 926M | 2.27B | 2.45B |
| Total Liabilities | 1.34B | 1.76B | 1.95B | 870M | 1.78B | 1.95B |
| Shareholders' Equity | -807M | -1.13B | -1.38B | 56.3M | 491M | 500M |
| Cash & Short-term Investments | 278M | 303M | 166M | 341M | 605M | 590M |
| Cash Flow | ||||||
| Operating Cash Flow | -212M | -168M | -214M | -189M | -218M | -95.4M |
| Capital Expenditure | 11.8M | 18.4M | 34.6M | 22.1M | 27.3M | 47.9M |
| Free Cash Flow | -224M | -187M | -249M | -211M | -245M | -143M |
| Ratios | ||||||
| ROE | - | - | - | -1,252.8% | -49.9% | -36.0% |
| ROA | -48.8% | -45.9% | -38.0% | -76.2% | -10.8% | -7.3% |
| Net Profit Margin | -100.5% | -90.4% | -40.3% | -101.8% | -19.3% | -11.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Tempus AI dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | USD 5.63M | 0.03 | - |
| 2023 | USD 5.63M | 0.03 | - |
| 2022 | USD 5.63M | 0.03 | - |
| 2021 | USD 5.63M | 0.03 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Tempus AI
- Insiders 36.15%
- Institutions 57.68%
- Public & others 6.17%
- Shares outstanding 177M
- Free float 126M
Tempus AI company profile
- Company name
- Tempus AI
- Ticker
- F3M.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Information Services
- Employees
- 3,800
- Fiscal year end
- December
- Address
- 600 West Chicago Avenue, Chicago, IL, United States, 60654
- Phone
- 800 976 5448
- Website
- tempus.com
About Tempus AI
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Tempus AI management
10- Mr. Eric P. Lefkofsky J.D.Co-Founder, CEO, President & Chairman · born 1970
- Mr. James RogersChief Financial Officer · born 1987
- Mr. Erik PhelpsExecutive VP and Chief Administrative & Legal Officer · born 1971
- Mr. Andrew PolovinChief Legal Officer · born 1974
- Mr. Ryan FukushimaChief Executive Officer of Data & Apps · born 1985
- Mr. Ryan M. Bartolucci CPAChief Accounting Officer · born 1982
- Mr. Shane ColleyChief Technology Officer
- Dr. Kate A. Sasser Ph.D.Chief Scientific Officer · born 1978
- Ms. Elizabeth KrutoholowVice President of Investor Relations & Competitive Intelligence
- Ms. Christina AntoniouSenior VP & Head of Corporate Development